Skip to main content

Table 2 Demographic Characteristics

From: Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

Safety population   AC-1202
N = 86
Placebo
N = 66
Age Mean (± SD)
Median
76.9 (± 8.9)
78.0
76.8 (± 7.4)
78.0
  Range (52 – 93) (51 – 89)
Height (cms) Mean (± SD) 165.2 (± 11.4) 163.2 (± 16.4)
  Median 163.8 164.6
  Range (142.2 – 190.1) (114.3 – 185.4)
Weight (kg) Mean (± SD) 69.0 (± 15.15) 70.6 (± 13.7)
  Median 69.2 67.8
  Range (34.3 – 100.2) (47.6 – 100.2)
Sex n (%) Male 36 (41.7) 31 (47.0)
  Female 50 (58.1) 35 (53.0)
Race n (%) Caucasian 78 (90.7) 61 (92.4)
  Black 1 (1.2) 0
  Hispanic 7 (8.1) 5 (7.6)
Level of Education n (%) Graduate/Professional Training 17 (19.8) 7 (10.6)
  Some college 15 (17.4) 17 (25.8)
  High School 49 (57.0) 34 (51.5)
  Grade School 5 (5.8) 8 (12.1)
AD medications n (%)* Aricept™ 43 (50) 28 (42.4)
  Exelon™ 11 (12.8) 11 (16.7)
  Namenda™ 32 (37.2) 31 (47)
  Reminyl™/Razadyne™ 3 (3.5) 9 (13.6)
Genotyped population   AC-1202
N = 67
Placebo
N = 57
APOE Genotype n (%) 3/2 4 (6.0) 2 (3.5)
  3/3 25 (37.3) 24 (42.1)
  4/2
4/3
3 (4.9)
31 (46.3)
0
21 (36.8)
  4/4 4 (6.0) 10 (17.5)
  Total E4(+) 38 (56.7) 31 (54.4)
  Total E4(-) 29 (43.3) 26 (45.6)
ITT population   AC -1202
N = 77
Placebo
N = 63
Baseline MMSE Mean (± SD) 19.68 (± 4.48) 19.48 (± 4.37)
  Median 20.00 20.00
  Range (10 – 28) (8 – 29)
  95% CI 18.66, 20.69 18.37, 20.58
Baseline ADAS-Cog Mean (± SD) 23.88 (± 9.17) 23.35 (± 8.7)
  Median 23.67 23.00
  Range (7.00 – 54.33) (11.33 – 62.00)
  95% CI 21.80, 25.96 21.16, 25.54
  1. *Some participants were on more than one AD medication